KalVista Pharmaceuticals Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
/ 
Frequently asked questions
To buy KalVista Pharmaceuticals Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for KalVista Pharmaceuticals Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for KalVista Pharmaceuticals Inc. is KALV:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
KalVista Pharmaceuticals Inc. has its primary listing on NASDAQ. You can trade KalVista Pharmaceuticals Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, KalVista Pharmaceuticals Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include KalVista Pharmaceuticals Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like KalVista Pharmaceuticals Inc..